TransMedics (TMDX) Common Equity (2018 - 2026)

TransMedics' Common Equity history runs 9 years deep, the most recent figure standing at $494.0 million for Q1 2026.

• On a quarterly basis, Common Equity rose 85.5% year-over-year to $494.0 million in Q1 2026; TTM through Mar 2026 was $494.0 million, a 85.5% increase from a year earlier, with the FY2025 full-year figure at $473.1 million, up 106.95% from the prior year.
• Common Equity grew to $494.0 million in Q1 2026 per TMDX's latest filing, from $473.1 million in the prior quarter.
• Across five years, Common Equity topped out at $494.0 million in Q1 2026 and bottomed at $50.9 million in Q2 2022.
• The 5-year median for Common Equity is $189.9 million (2024), against an average of $222.5 million.
• Across the five-year window, Common Equity slumped 42.78% in 2022 and jumped 221.52% in 2023, its largest moves.
• Year by year, Common Equity stood at $187.4 million in 2022, then declined by 26.78% to $137.2 million in 2023, then jumped by 66.62% to $228.6 million in 2024, then soared by 106.95% to $473.1 million in 2025, then climbed by 4.42% to $494.0 million in 2026.
• Per Business Quant, the three latest TMDX Common Equity figures stand at $494.0 million (Q1 2026), $473.1 million (Q4 2025), and $355.2 million (Q3 2025).